Skip to main content

Table 2 Incidence of thromboembolic toxicity in prospective studies using cisplatin

From: Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature

Trial Chemotherapy XRT Toxicity No. CTX Pts
Keys et al. [5] (cervix) Cis 40 mg/m2 q wk X 6 concurrent 75 Gy to pt A 0 deaths 1 Grade 3&1 Grade 4 CVT (NOS) 183
Benedetti et al. [3] (cervix) Cis 40–80 mg/m2 q wk X 6–8 concurrent 45–50 Gy WP 20–30 Gy Low Dose Rate 0 deaths 201
Morris et al. [2] (cervix) Cis 75 mg/m2 and 5-FU 4000 mg/m2 q wk X 3 concurrent 85 Gy to pt A 1 death (NOS) 193
Pearcey et al. [6] (cervix) Cis 40 mg/m2 q wk X 5 concurrent 80 Gy to pt A 1 death (SBP) 3 Grade 3 CVT (NOS) 127
Peters et al. [7] (cervix) Cis 70 mg/m2 and 5-FU 1000 mg/m2 q wk X 4 concurrent 4930 WP @ 170 cGy/day 1 death (Bilateral ureteral obstruction) 127
Rose et al. [8] (cervix) Cis 40 mg/m2 q wk X 6 concurrent or Cis/5-FU/Hydroxyurea or Hydroxyurea 80 Gy to pt A 0 deaths 2 Grade 3 CVT (NOS), with 3 drug regimen 526
Malfetano et al. [4] (cervix) Cis 1 mg/Kg q wk with XRT 45 Gy PA, WP 4–5000 cGy and 3–4000 cGy Low Dose Rate 2 Grade 5 CVT (from PE) 67
  1. NOS = Not otherwise specified CVT = Cardiovascular Toxicity SBP: Small Bowel Perforation Cis = Cisplatin 5FU = 5 Fluorouracil WP = Whole Pelvis Gy = Gray